Custom RNA vaccines show promise in targeting aggressive breast cancer
NCT ID NCT02316457
First seen Mar 21, 2026 · Last updated May 24, 2026 · Updated 13 times
Summary
This early-phase study tested personalized RNA vaccines designed to train the immune system to attack each patient's unique tumor. 42 people with triple negative breast cancer received custom-made vaccines. The main goal was to check safety and see if the vaccines triggered an immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER (TRIPLE NEGATIVE BREAST CANCER (TNBC)) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dr. Horst Schmidt-Kliniken Wiesbaden
Wiesbaden, 65199, Germany
-
Johannes Gutenberg University
Mainz, RLP, 55131, Germany
-
National Center for Tumor Diseases (NCT)
Heidelberg, 69120, Germany
-
Uppsala University Hospital
Uppsala, 75185, Sweden
Conditions
Explore the condition pages connected to this study.